Identification of immune-related candidate biomarkers in plasma of patients with sporadic vestibular schwannoma-Reference-Cited by-同舟云学术

Identification of immune-related candidate biomarkers in plasma of patients with sporadic vestibular schwannoma

Published:2023-11-10 Issue:45 Volume:9 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Vasilijic Sasa¹²^ORCID,Atai Nadia A.²,Hyakusoku Hiroshi²³^ORCID,Worthington Steven⁴^ORCID,Ren Yin²,Sagers Jessica E.²^ORCID,Sahin Mehmet I.²^ORCID,Brown Alyssa²^ORCID,Reddy Rohan¹,Malhotra Charvi¹,Fujita Takeshi²^ORCID,Landegger Lukas D.²^ORCID,Lewis Richard²⁵^ORCID,Welling D. Bradley²^ORCID,Stankovic Konstantina M.¹²⁶⁷^ORCID

Affiliation:

1. Department of Otolaryngology–Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA.

2. Department of Otolaryngology–Head and Neck Surgery, Massachusetts Eye and Ear and Harvard Medical School, Boston, MA, USA.

3. Department of Otorhinolaryngology, Yokosuka Kyosai Hospital, Kanagawa, Japan.

4. Harvard Institute for Quantitative Social Science, Harvard University, Cambridge, MA, USA.

5. Department of Neurology, Harvard Medical School, Boston, MA, USA.

6. Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.

7. Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.

Abstract

Vestibular schwannoma (VS) is an intracranial tumor arising from neoplastic Schwann cells and typically presenting with hearing loss. The traditional belief that hearing deficit is caused by physical expansion of the VS, compressing the auditory nerve, does not explain the common clinical finding that patients with small tumors can have profound hearing loss, suggesting that tumor-secreted factors could influence hearing ability in VS patients. We conducted profiling of patients’ plasma for 66 immune-related factors in patients with sporadic VS ( N > 170) and identified and validated candidate biomarkers associated with tumor size (S100B) and hearing (MCP-3). We further identified a nine-biomarker panel (TNR-R2, MIF, CD30, MCP-3, IL-2R, BLC, TWEAK, eotaxin, and S100B) with outstanding discriminatory ability for VS. These findings revealed possible therapeutic targets for VS, providing a unique diagnostic tool that may predict hearing change and tumor growth in VS patients, and may inform the timing of tumor resection to preserve hearing.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Link

https://www.science.org/doi/pdf/10.1126/sciadv.adf7295

Reference45 articles.

1. Analysis of patterns of care of brain tumor patients in the United States: A study of the Brain Tumor Section of the AANS and the CNS and the Commission on Cancer of the ACS;Mahaley M. S.;Clin. Neurosurg.,1990

2. Vestibular (Acoustic) Schwannomas: Histologic Features in Neurofibromatosis 2 and in Unilateral Cases

3. Loud Noise Exposure and Acoustic Neuroma

4. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation

5. Management of 1000 vestibular schwannomas (acoustic neuromas): Clinical presentation;Matthies C.;Neurosurgery,1997

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Age, preoperative tumor volume and widening of the internal acoustic meatus are independent factors associated with poor preoperative hearing in vestibular schwannoma patients – results of a single-center retrospective analysis;2023-12-07